Natera (NASDAQ:NTRA) Price Target Raised to $180.00 at Canaccord Genuity Group

Natera (NASDAQ:NTRA) had its target price increased by Canaccord Genuity Group from $165.00 to $180.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

Several other research analysts have also issued reports on NTRA. Craig Hallum boosted their target price on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Morgan Stanley raised their price objective on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Robert W. Baird raised their price objective on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. increased their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Finally, The Goldman Sachs Group upped their price objective on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus target price of $153.67.

Natera Stock Up 4.4 %

Natera stock opened at $167.60 on Friday. Natera has a one year low of $58.53 and a one year high of $175.63. The stock has a fifty day moving average of $155.07 and a 200 day moving average of $129.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The stock has a market cap of $22.13 billion, a PE ratio of -95.23 and a beta of 1.65.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter last year, the business posted ($0.95) earnings per share. The firm’s revenue was up 63.9% on a year-over-year basis. As a group, sell-side analysts predict that Natera will post -1.61 EPS for the current year.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 1,196 shares of Natera stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $141,379.16. Following the sale, the insider now owns 110,695 shares of the company’s stock, valued at $13,085,255.95. The trade was a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 4,523 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20. Following the transaction, the chief executive officer now directly owns 191,163 shares in the company, valued at approximately $24,927,655.20. This trade represents a 2.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 127,932 shares of company stock valued at $20,635,430 in the last 90 days. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Natera

A number of institutional investors have recently bought and sold shares of NTRA. Chartwell Investment Partners LLC lifted its stake in shares of Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the period. Cerity Partners LLC increased its holdings in Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after buying an additional 18,316 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Natera during the third quarter worth $385,000. Jag Capital Management LLC boosted its position in Natera by 8.8% during the 3rd quarter. Jag Capital Management LLC now owns 175,590 shares of the medical research company’s stock valued at $22,291,000 after purchasing an additional 14,159 shares during the period. Finally, First Turn Management LLC bought a new position in Natera in the 3rd quarter worth about $19,760,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.